Phase II Study of Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel in Untreated Metastatic Adenocarcinoma of the Pancreas
Summary
The purpose of this phase II trial is to evaluate the safety and efficacy of modified FOLFIRINOX (mFFX) alternated with biweekly Gemcitabine plus Nab-Paclitaxel as a combined first-line therapy in patients with metastatic pancreatic cancer.
General Information
NCT#: NCT04672005
Study ID: Pro2020002395
Trial Phase: Phase II
Trial Sponsor: Lyudmyla Berim
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, FOLFIRINOX